Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis

Mucosal Immunology

Volumn 7, Issue 1, 2014, Pages 114-123

  Keely, S ^a,b   Campbell, E L ^c   Baird, A W ^d   Hansbro, P M ^a,b   Shalwitz, R A ^e   Kotsakis, A ^e   McNamee, E N ^c   Eltzschig, H K ^c   Kominsky, D J ^c   Colgan, S P ^c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e Aerpio Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKB 4924; CYTOKINE; ENDOTOXIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG RESPONSE; DRUG TARGETING; ENZYME INHIBITION; EPITHELIUM; FEMALE; FEVER; HYPOTHERMIA; IMMUNOMODULATION; INNATE IMMUNITY; INTESTINE MUCOSA PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WEIGHT REDUCTION;

ANIMALS; COLITIS; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; FEMALE; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; MICE; PERMEABILITY; PIPERAZINES; PROLYL HYDROXYLASES; PROLYL-HYDROXYLASE INHIBITORS; PYRIDONES; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886073769     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.29     Document Type: Article

References (49)

1. Karrasch, T. & Jobin, C. Wound healing responses at the gastrointestinal epithelium: a close look at novel regulatory factors and investigative approaches. Z Gastroenterol. 47, 1221-1229 (2009).
2. Lawrance, I.C. et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J. Gastroenterol. Hepatol. 25, 1732-1738 (2010).
3. Pastor Rojo, O., Lopez San Roman, A., Albeniz Arbizu, E., de la Hera Martinez, A., Ripoll Sevillano, E. & Albillos Martinez, A. Serum lipopolysaccharide- binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13, 269-277 (2007).
4. Lodes, M.J. et al. Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Invest. 113, 1296-1306 (2004).
5. Ward, J.B., Lawler, K., Amu, S., Taylor, C.T., Fallon, P.G. & Keely, S.J. Hydroxylase inhibition attenuates colonic epithelial secretory function and ameliorates experimental diarrhea. FASEB J. 25, 535-543 (2011).
6. Robinson, A., Keely, S., Karhausen, J., Gerich,M.E., Furuta, G.T. &Colgan, S.P. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 134, 145-155 (2008).
7. Keely, S. et al. Selective induction of integrin beta1 by hypoxia-inducible factor: implications for wound healing. FASEB J. 23, 1338-1346 (2009).
8. Tambuwala, M.M. et al. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 139, 2093-2101 (2010).
9. Cummins, E.P. et al. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 134, 156-165 (2008).
10. Berra, E., Benizri, E., Ginouves, A., Volmat, V., Roux, D. & Pouyssegur, J.H.I.F. prolyl-hydroxylase 2 is the key oxygen sensor setting low steadystate levels of HIF-1alpha in normoxia. EMBO J. 22, 4082-4090 (2003).
11. Cummins, E.P. et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc. Natl. Acad. Sci. USA 103, 18154-18159 (2006).
12. Walmsley, S.R. et al. Neutrophils from patients with heterozygous germline mutations in the von Hippel Lindau protein (pVHL) display delayed apoptosis and enhanced bacterial phagocytosis. Blood 108, 3176-3178 (2006).
13. Walmsley, S.R. et al. Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J. Exp. Med. 201, 105-115 (2005).
14. Fritzenwanger, M., Jung, C., Goebel, B., Lauten, A. & Figulla, H.R. Impact of short-term systemic hypoxia on phagocytosis, cytokine production, and transcription factor activation in peripheral blood cells. Mediators Inflamm. 2011, 429501 (2011).
15. Anand, R.J. et al. Hypoxia causes an increase in phagocytosis by macrophages in a HIF-1alpha-dependent manner. J. Leukoc. Biol. 82, 1257-1265 (2007).
16. Hams, E. et al. The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by b1 cells. Shock 36, 295-302 (2011).
17. Okumura, C.Y. et al. A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection. J. Mol. Med. (Berl) 90, 1079-1089 (2012).
18. Leon, L.R. Hypothermia in systemic inflammation: role of cytokines. Front. Biosci. 9, 1877-1888 (2004).
19. Furuta, G.T. et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J. Exp. Med. 193, 1027-1034 (2001).
20. Synnestvedt, K. et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxiainducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110, 993-1002 (2002).
21. Karhausen, J., Furuta, G.T., Tomaszewski, J.E., Johnson, R.S., Colgan, S.P. & Haase, V.H. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J. Clin. Invest. 114, 1098-1106 (2004).
22. Kontoyiannis, D., Pasparakis, M., Pizarro, T.T., Cominelli, F. & Kollias, G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNFAU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10, 387-398 (1999).
23. Welcker, K., Martin, A., Kolle, P., Siebeck, M. & Gross, M. Increased intestinal permeability in patients with inflammatory bowel disease. Eur. J. Med. Res. 9, 456-460 (2004).
24. Takeuchi, K., Maiden, L. & Bjarnason, I. Genetic aspects of intestinal permeability in inflammatory bowel disease. Novartis Found. Symp. 263, 151-158 (2004). discussion 159-163, 211-158.
25. Oriishi, T., Sata, M., Toyonaga, A., Sasaki, E. & Tanikawa, K. Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A. Gut 36, 891-896 (1995).
26. Caradonna, L., Amati, L., Lella, P., Jirillo, E. & Caccavo, D. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease. Am. J. Gastroenterol. 95, 1495-1502 (2000).
27. Gardiner, K.R. et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 36, 897-901 (1995).
28. Barbier, M., Cherbut, C., Aube, A.C., Blottiere, H.M. & Galmiche, J.P. Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats. Gut 43, 783-790 (1998).
29. Kokura, S., Yoshida, N. & Yoshikawa, T. Anoxia/reoxygenation-induced leukocyte-endothelial cell interactions. Free Radic. Biol.Med. 33, 427-432 (2002).
30. Haddad, J.J. Science review: redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for hypoxiainducible factor-1alpha. Crit. Care 7, 47-54 (2003).
31. Saadi, S.,Wrenshall, L.E. & Platt, J.L. Regional manifestations and control of the immune system. FASEB J. 16, 849-856 (2003).
32. Elks, P.M. et al. Activation of hypoxia-inducible factor-1alpha (Hif-1alpha) delays inflammation resolution by reducing neutrophil apoptosis and reverse migration in a zebrafish inflammation model. Blood 118, 712-722 (2011).
33. Jantsch, J. et al. Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function. J. Immunol. 180, 4697-4705 (2008).
34. Jeong, H.J. et al. Activation of hypoxia-inducible factor-1 regulates human histidine decarboxylase expression. Cell. Mol. Life Sci. 66, 1309-1319 (2009).
35. MacManus, C.F., Campbell, E.L., Keely, S., Burgess, A., Kominsky, D.J. & Colgan, S.P. Anti-inflammatory actions of adrenomedullin through fine tuning of HIF stabilization. FASEB J. 25, 1856-1864 (2011).
36. Nizet, V. & Johnson, R.S. Interdependence of hypoxic and innate immune responses. Nat. Rev. Immunol. 9, 609-617 (2009).
37. Frick, J.S., MacManus, C.F., Scully, M., Glover, L.E., Eltzschig, H.K. & Colgan, S.P. Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. J. Immunol. 182, 4957-4964 (2009).
38. Taylor, C.T. & Colgan, S.P. Hypoxia and gastrointestinal disease. J. Mol. Med. (Berl) 85, 1295-1300 (2007).
39. Collins, C.B. et al. Flt3 ligand expands CD103+ dendritic cells and FoxP3+ T regulatory cells, and attenuates Crohn's-like murine ileitis. Gut 61, 1154-1162 (2012).
40. Campbell, E.L. et al. Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc. Natl. Acad. Sci. USA 107, 14298-14303 (2010).
41. Keely, S. et al. In vitro and ex vivo intestinal tissue models to measure mucoadhesion of poly (methacrylate) and N-trimethylated chitosan polymers. Pharm. Res. 22, 38-49 (2005).
42. Barthe, L., Woodley, J. & Houin, G. Gastrointestinal absorption of drugs: methods and studies. Fundam. Clin. Pharmacol. 13, 154-168 (1999).
43. Keely, S., Feighery, L., Campion, D.P., O'Brien, L., Brayden, D.J. & Baird, A.W. Chloride-led disruption of the intestinal mucous layer impedes Salmonella invasion: evidence for an 'enteric tear' mechanism. Cell. Physiol. Biochem. 28, 743-752 (2011).
44. Keely, S. et al. Dexamethasone-pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers. J. Control Release 135, 35-43 (2009).
45. Coxon, A. et al. A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 5, 653-666 (1996).
46. Mizgerd, J.P. et al. Combinatorial requirements for adhesion molecules in mediating neutrophil emigration during bacterial peritonitis in mice. J. Leukoc. Biol. 64, 291-297 (1998).
47. Fortier, A.H. & Falk, L.A. Isolation of murine macrophages. Curr. Protoc. Immunol. Chapter 14.1, 1-9 (2001).
48. Asfaha, S., MacNaughton, W.K., Appleyard, C.B., Chadee, K. & Wallace, J.L. Persistent epithelial dysfunction and bacterial translocation after resolution of intestinal inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 281, G635-G644 (2001).
49. Llopis, M., Antolin, M., Guarner, F., Salas, A. & Malagelada, J.R. Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid. Gut 54, 955-959 (2005).